Jacobs Levy Equity Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17.9M Sell
19,470
-4,280
-18% -$4.34M 0.08% 225
2025
Q4
$25.5M Buy
+23,750
New +$22.7M 0.1% 174
2025
Q3
Sell
-6,843
Closed -$5.33M 1043
2025
Q2
$5.33M Sell
6,843
-11,245
-62% -$8.74M 0.02% 420
2025
Q1
$14.9M Buy
18,088
+15,071
+500% +$12.5M 0.06% 271
2024
Q4
$2.33M Sell
3,017
-13,255
-81% -$11M 0.01% 569
2024
Q3
$14.4M Sell
16,272
-4,609
-22% -$4.14M 0.06% 278
2024
Q2
$18.9M Buy
20,881
+9,807
+89% +$7.84M 0.08% 230
2024
Q1
$8.62M Buy
11,074
+8,651
+357% +$6.16M 0.04% 324
2023
Q4
$1.41M Sell
2,423
-2,060
-46% -$1.2M 0.01% 665
2023
Q3
$2.41M Buy
+4,483
New +$2.31M 0.01% 533
2023
Q2
Sell
-51,687
Closed -$17.8M 1035
2023
Q1
$17.8M Sell
51,687
-99,526
-66% -$33.6M 0.11% 209
2022
Q4
$55.3M Buy
151,213
+145,112
+2,378% +$51.5M 0.37% 72
2022
Q3
$1.97M Buy
+6,101
New +$1.93M 0.02% 562
2021
Q1
Sell
-203,078
Closed -$34.3M 1073
2020
Q4
$34.3M Sell
203,078
-156,197
-43% -$23.3M 0.3% 84
2020
Q3
$53.2M Sell
359,275
-204,763
-36% -$31.7M 0.55% 39
2020
Q2
$92.6M Buy
564,038
+150,202
+36% +$23.1M 1% 9
2020
Q1
$57.4M Buy
413,836
+320,315
+343% +$44M 0.74% 20
2019
Q4
$12.3M Buy
93,521
+65,268
+231% +$7.57M 0.12% 208
2019
Q3
$3.16M Sell
28,253
-18,524
-40% -$2.06M 0.04% 419
2019
Q2
$5.18M Sell
46,777
-330
-0.7% -$38.9K 0.07% 338
2019
Q1
$6.11M Sell
47,107
-68,962
-59% -$8.39M 0.09% 294
2018
Q4
$13.4M Sell
116,069
-54,250
-32% -$6.06M 0.24% 112
2018
Q3
$18.3M Sell
170,319
-317,230
-65% -$31.7M 0.26% 115
2018
Q2
$41.6M Buy
487,549
+4,760
+1% +$391K 0.65% 12
2018
Q1
$37.4M Buy
482,789
+269,850
+127% +$21.7M 0.62% 14
2017
Q4
$18M Buy
212,939
+109,620
+106% +$9.33M 0.32% 103
2017
Q3
$8.84M Sell
103,319
-192,981
-65% -$15.8M 0.17% 182
2017
Q2
$24.4M Sell
296,300
-45,340
-13% -$3.7M 0.52% 39
2017
Q1
$28.7M Sell
341,640
-166,737
-33% -$13.4M 0.58% 33
2016
Q4
$37.4M Buy
508,377
+138,640
+37% +$10.3M 0.72% 16
2016
Q3
$29.7M Buy
369,737
+151,140
+69% +$12.1M 0.53% 42
2016
Q2
$17.2M Sell
218,597
-295,021
-57% -$22.2M 0.36% 70
2016
Q1
$37M Sell
513,618
-60,970
-11% -$4.61M 0.78% 14
2015
Q4
$48.4M Buy
574,588
+127,820
+29% +$10.6M 0.96% 16
2015
Q3
$37.4M Buy
446,768
+438,057
+5,029% +$37M 0.77% 22
2015
Q2
$727K Sell
8,711
-222,929
-96% -$17M 0.01% 513
2015
Q1
$16.8M Sell
231,640
-259,229
-53% -$18.5M 0.29% 119
2014
Q4
$33.9M Sell
490,869
-49,010
-9% -$3.31M 0.58% 39
2014
Q3
$35M Sell
539,879
-690
-0.1% -$43.7K 0.58% 37
2014
Q2
$33.6M Buy
540,569
+379,602
+236% +$22.6M 0.56% 38
2014
Q1
$9.47M Sell
160,967
-722,623
-82% -$40.3M 0.16% 181
2013
Q4
$45.1M Sell
883,590
-3,330
-0.4% -$167K 0.68% 24
2013
Q3
$44.6M Buy
886,920
+19,280
+2% +$1.01M 0.76% 20
2013
Q2
$42.6M Buy
+867,640
New +$47.2M 0.75% 19

Other funds holding LLY

Jacobs Levy Equity Management's LLY Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its Eli Lilly (LLY) stake by 18% in Q1 2026, selling an estimated $4.34M and leaving 19,470 shares worth $17.9M. The position accounts for 0.08% of the portfolio, ranked #225.

Jacobs Levy Equity Management first reported a position in LLY in Q2 2013 and has held it in 44 quarters since. The position peaked at $92.6M in Q2 2020. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Jacobs Levy Equity Management held 19,470 shares of Eli Lilly worth $17.9M as of Q1 2026.
  • Jacobs Levy Equity Management sold 4,280 Eli Lilly shares in Q1 2026, an estimated $4.34M.
  • Eli Lilly made up 0.08% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #225 holding.
  • Jacobs Levy Equity Management first reported a position in Eli Lilly in Q2 2013 and has held it in 44 quarters since.
  • Jacobs Levy Equity Management's Eli Lilly position peaked at $92.6M in Q2 2020.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.